E X A M S E R I E S
NR565 / NR 565 Advanced
Pharmacology Fundamentals
Midterm Exam Review
130 Q & A · Highly Rated Question Bank
A complete midterm exam review with 130 board-style questions, verified
correct answers, and detailed rationales aligned to the Chamberlain University
NR565 course syllabus, AACN Essentials of Master's Education, and
Advanced Practice Pharmacotherapeutics standards (2026/2027 Edition).
130 11
Board-style questions with rationales Sections by NR565 blueprint
25/50/25 A+
Recall / Application / Analysis Verified answers · Curriculum-
cognitive mix aligned
EDITION
Chamberlain College · Verified Answers · Instant PDF Download
, NR565 Advanced Pharmacology Fundamentals — Midterm
Exam Review
130 questions · Correct answers · Detailed rationales. Use this bank to assess readiness
and reinforce weak areas before exam day. Cognitive levels approximate the NR565
midterm distribution: 25% recall, 50% application, 25% analysis.
EDITION
SECTION 1: PHARMACOKINETICS & PHARMACODYNAMICS
Q 1 · A P P L I C AT I O N · N R 5 6 5 M I D T E R M R E V I E W
1. A patient is prescribed a weak base with a pKa of 8.2. If the urine is alkalinized from pH 6.0 to
7.5 using sodium bicarbonate, what is the expected effect on renal elimination of the drug?
A. Decreased elimination because a larger fraction becomes unionized and is reabsorbed
B. Increased elimination because a greater fraction becomes ionized and is trapped in the
tubule *[CORRECT]*
C. No change because pKa is independent of urine pH
D. Decreased elimination because alkaline urine enhances tubular secretion of weak bases
CORRECT ANSWER: B
Rationale: Weak bases become more ionized as pH rises toward their pKa (Henderson-Hasselbalch).
Ionized drug cannot cross tubular membranes for reabsorption, so it remains trapped in the urine and is
excreted. This ion-trapping principle is the rationale for urine alkalinization in weak-base overdose.
,Q 2 · A P P L I C AT I O N · N R 5 6 5 M I D T E R M R E V I E W
2. A patient with severe hepatic cirrhosis is prescribed a drug that undergoes extensive first-pass
metabolism. How should the prescriber anticipate the oral bioavailability of this drug?
A. Decreased, requiring a higher oral dose
B. Increased, requiring a lower oral dose *[CORRECT]*
C. Unchanged, because renal elimination compensates
D. Decreased, because hepatic enzymes are upregulated
CORRECT ANSWER: B
Rationale: Cirrhosis reduces hepatocyte mass and may create portosystemic shunting, diminishing
first-pass metabolism. A larger fraction of the oral dose reaches the systemic circulation, increasing
bioavailability and the risk of toxicity. A lower starting dose with careful titration is therefore indicated.
Q3 · RECALL · NR565 MIDTERM REVIEW
3. A drug has a half-life of 8 hours. Approximately how long will it take to reach steady state with
continuous dosing, and when should therapeutic drug monitoring be performed?
A. 8 hours; monitor immediately after the first dose
B. 16 hours; monitor after two doses
C. Approximately 40 hours (5 half-lives); monitor after steady state is achieved *
[CORRECT]*
D. Approximately 80 hours (10 half-lives); monitor only if toxicity is suspected
CORRECT ANSWER: C
Rationale: Steady state is reached after roughly 4-5 half-lives regardless of dose or dosing interval.
With a half-life of 8 hours, 5 half-lives equals 40 hours. Drawing drug levels before steady state leads to
falsely low or misleading values that may prompt unsafe dose escalations.
, Q 4 · A N A LY S I S · N R 5 6 5 M I D T E R M R E V I E W
4. A 72-year-old patient taking warfarin (metabolized by CYP2C9) is started on fluconazole for
oral candidiasis. The INR rises to 7.4 within 10 days. Which mechanism best explains this
interaction?
A. Fluconazole induces CYP2C9, increasing warfarin clearance
B. Fluconazole inhibits CYP2C9, reducing warfarin clearance and raising INR *[CORRECT]*
C. Fluconazole displaces warfarin from plasma proteins only, with no change in clearance
D. Fluconazole increases vitamin K absorption from the gut
CORRECT ANSWER: B
Rationale: Fluconazole is a potent inhibitor of CYP2C9 (and to a lesser extent CYP3A4). Inhibiting S-
warfarin metabolism decreases clearance, increases plasma concentration, and elevates INR. The
interaction is dose-dependent and may persist for weeks after fluconazole is stopped due to its long
half-life.
Q5 · RECALL · NR565 MIDTERM REVIEW
5. Which drug property most directly increases the apparent volume of distribution (Vd)?
A. High plasma protein binding
B. High lipophilicity and low ionization at physiologic pH *[CORRECT]*
C. Extensive ionization at physiologic pH
D. Large molecular size and high water solubility
CORRECT ANSWER: B
Rationale: Lipophilic, unionized drugs readily cross cell membranes and sequester in adipose and lipid-
rich compartments, producing a large apparent Vd. High protein binding, extensive ionization, and large
molecular size all tend to keep drug within the vascular space, reducing Vd.
NR565 / NR 565 Advanced
Pharmacology Fundamentals
Midterm Exam Review
130 Q & A · Highly Rated Question Bank
A complete midterm exam review with 130 board-style questions, verified
correct answers, and detailed rationales aligned to the Chamberlain University
NR565 course syllabus, AACN Essentials of Master's Education, and
Advanced Practice Pharmacotherapeutics standards (2026/2027 Edition).
130 11
Board-style questions with rationales Sections by NR565 blueprint
25/50/25 A+
Recall / Application / Analysis Verified answers · Curriculum-
cognitive mix aligned
EDITION
Chamberlain College · Verified Answers · Instant PDF Download
, NR565 Advanced Pharmacology Fundamentals — Midterm
Exam Review
130 questions · Correct answers · Detailed rationales. Use this bank to assess readiness
and reinforce weak areas before exam day. Cognitive levels approximate the NR565
midterm distribution: 25% recall, 50% application, 25% analysis.
EDITION
SECTION 1: PHARMACOKINETICS & PHARMACODYNAMICS
Q 1 · A P P L I C AT I O N · N R 5 6 5 M I D T E R M R E V I E W
1. A patient is prescribed a weak base with a pKa of 8.2. If the urine is alkalinized from pH 6.0 to
7.5 using sodium bicarbonate, what is the expected effect on renal elimination of the drug?
A. Decreased elimination because a larger fraction becomes unionized and is reabsorbed
B. Increased elimination because a greater fraction becomes ionized and is trapped in the
tubule *[CORRECT]*
C. No change because pKa is independent of urine pH
D. Decreased elimination because alkaline urine enhances tubular secretion of weak bases
CORRECT ANSWER: B
Rationale: Weak bases become more ionized as pH rises toward their pKa (Henderson-Hasselbalch).
Ionized drug cannot cross tubular membranes for reabsorption, so it remains trapped in the urine and is
excreted. This ion-trapping principle is the rationale for urine alkalinization in weak-base overdose.
,Q 2 · A P P L I C AT I O N · N R 5 6 5 M I D T E R M R E V I E W
2. A patient with severe hepatic cirrhosis is prescribed a drug that undergoes extensive first-pass
metabolism. How should the prescriber anticipate the oral bioavailability of this drug?
A. Decreased, requiring a higher oral dose
B. Increased, requiring a lower oral dose *[CORRECT]*
C. Unchanged, because renal elimination compensates
D. Decreased, because hepatic enzymes are upregulated
CORRECT ANSWER: B
Rationale: Cirrhosis reduces hepatocyte mass and may create portosystemic shunting, diminishing
first-pass metabolism. A larger fraction of the oral dose reaches the systemic circulation, increasing
bioavailability and the risk of toxicity. A lower starting dose with careful titration is therefore indicated.
Q3 · RECALL · NR565 MIDTERM REVIEW
3. A drug has a half-life of 8 hours. Approximately how long will it take to reach steady state with
continuous dosing, and when should therapeutic drug monitoring be performed?
A. 8 hours; monitor immediately after the first dose
B. 16 hours; monitor after two doses
C. Approximately 40 hours (5 half-lives); monitor after steady state is achieved *
[CORRECT]*
D. Approximately 80 hours (10 half-lives); monitor only if toxicity is suspected
CORRECT ANSWER: C
Rationale: Steady state is reached after roughly 4-5 half-lives regardless of dose or dosing interval.
With a half-life of 8 hours, 5 half-lives equals 40 hours. Drawing drug levels before steady state leads to
falsely low or misleading values that may prompt unsafe dose escalations.
, Q 4 · A N A LY S I S · N R 5 6 5 M I D T E R M R E V I E W
4. A 72-year-old patient taking warfarin (metabolized by CYP2C9) is started on fluconazole for
oral candidiasis. The INR rises to 7.4 within 10 days. Which mechanism best explains this
interaction?
A. Fluconazole induces CYP2C9, increasing warfarin clearance
B. Fluconazole inhibits CYP2C9, reducing warfarin clearance and raising INR *[CORRECT]*
C. Fluconazole displaces warfarin from plasma proteins only, with no change in clearance
D. Fluconazole increases vitamin K absorption from the gut
CORRECT ANSWER: B
Rationale: Fluconazole is a potent inhibitor of CYP2C9 (and to a lesser extent CYP3A4). Inhibiting S-
warfarin metabolism decreases clearance, increases plasma concentration, and elevates INR. The
interaction is dose-dependent and may persist for weeks after fluconazole is stopped due to its long
half-life.
Q5 · RECALL · NR565 MIDTERM REVIEW
5. Which drug property most directly increases the apparent volume of distribution (Vd)?
A. High plasma protein binding
B. High lipophilicity and low ionization at physiologic pH *[CORRECT]*
C. Extensive ionization at physiologic pH
D. Large molecular size and high water solubility
CORRECT ANSWER: B
Rationale: Lipophilic, unionized drugs readily cross cell membranes and sequester in adipose and lipid-
rich compartments, producing a large apparent Vd. High protein binding, extensive ionization, and large
molecular size all tend to keep drug within the vascular space, reducing Vd.
